US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apogee Therapeutics

40.98

+3.338.84%

Post-market: 40.980.00000.00%16:28 EDT

Volume:1.11M

Turnover:45.62M

Market Cap:2.39B

PE:-11.41

High:42.50

Open:38.45

Low:38.39

Close:37.65

Loading ...

Overview Company News Filings

Apogee Therapeutics Inc - to Initiate Phase 1B Trial of Apg279 Against Dupixent in 2025

THOMSON REUTERS

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?

Apogee Therapeutics to Host Conference Call to Report Interim Results From the Phase 1 Healthy Volunteer Trial for Apg990 and Provide Combination Strategy Update on March 3, 2025

THOMSON REUTERS

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Buy Rating Affirmed for Apogee Therapeutics: Promising Developments in Inflammatory Disease Treatments

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 Apex Trial of Apg777 in Patients With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS

Apogee Therapeutics Inc - Part a 16-Week Proof-of-Concept Data Expected Mid-2025

THOMSON REUTERS

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee (APOG) Stock Trades Down, Here Is Why

This Apogee Therapeutics Insider Increased Their Holding In The Last Year

Simply Wall St.

Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025

THOMSON REUTERS

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

THOMSON REUTERS

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/APGE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":40.98,"timestamp":1749240000000,"preClose":37.65,"halted":0,"volume":1112592,"hourTrading":{"tag":"盘后","latestPrice":40.98,"preClose":40.98,"latestTime":"16:28 EDT","volume":42824,"amount":1754927.52,"timestamp":1749241706952},"delay":0,"floatShares":37589079,"shares":58368834,"eps":-3.591044,"marketStatus":"Market Closed","change":3.33,"latestTime":"06-06 16:00:00 EDT","open":38.45,"high":42.4999,"low":38.39,"amount":45618259.055816,"amplitude":0.109161,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.591044,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":37.65,"preHourTrading":{"tag":"盘前","latestPrice":37.97,"preClose":37.65,"latestTime":"08:40 EDT","volume":4,"amount":151.88,"timestamp":1749213617264},"postHourTrading":{"tag":"盘后","latestPrice":40.98,"preClose":40.98,"latestTime":"16:28 EDT","volume":42824,"amount":1754927.52,"timestamp":1749241706952},"volumeRatio":1.2972026113972672,"impliedVol":1.8149,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","floatShares":37589079,"roa":"-19.65%","roe":"-27.85%","lyrEps":-3.300106,"volumeRatio":1.2972026113972672,"shares":58368834,"dividePrice":0,"high":42.4999,"amplitude":0.109161,"preClose":37.65,"low":38.39,"week52Low":26.2,"pbRate":"3.55","week52High":63.5,"institutionHeld":0,"latestPrice":40.98,"eps":-3.591044,"divideRate":0,"volume":1112592,"delay":0,"ttmEps":-3.591044,"open":38.45,"prevYearClose":45.3,"prevWeekClose":36.64,"prevMonthClose":36.64,"prevQuarterClose":37.36,"fiveDayClose":36.64,"twentyDayClose":37.81,"sixtyDayClose":38.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APGE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516468144","title":"Apogee Therapeutics Inc - to Initiate Phase 1B Trial of Apg279 Against Dupixent in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516468144","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516468144?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516758551","title":"Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516758551","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516758551?lang=en_us&edition=fundamental","pubTime":"2025-03-01 22:22","pubTimestamp":1740838921,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Apogee Therapeutics, Inc.  stands against the other small-cap stocks.The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year post-COVID. With the index hitting all-time highs, small-cap stocks can be a good option to explore with higher growth potential in the long term.However, the Russell 2000 small-cap index returned a little over 7% in 2024 compared to the 23% returns by the S&P 500. Over the past five years , the S&P 500 has almost doubled the return of the Russell 2000 small cap, with returns of 102% against 47%, respectively.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-inc-apge-best-142201193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","MNQmain","APGE","NQmain","PSQ","BK4139","USAW.SI","TSYW.SI","NVIW.SI","SQQQ","TQQQ","USJW.SI","QLD","QID"],"gpt_icon":1},{"id":"2516855301","title":"Apogee Therapeutics to Host Conference Call to Report Interim Results From the Phase 1 Healthy Volunteer Trial for Apg990 and Provide Combination Strategy Update on March 3, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516855301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516855301?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:00","pubTimestamp":1740776400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA4NDRYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516301503","title":"Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301503","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516301503?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:00","pubTimestamp":1740776400,"startTime":"0","endTime":"0","summary":"Webcast to be held Monday, March 3rd at 8:30 a.m. ETSAN FRANCISCO and BOSTON, Feb.  28, 2025  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company adva","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/28/3035028/0/en/Apogee-Therapeutics-to-Host-Conference-Call-to-Report-Interim-Results-from-the-Phase-1-Healthy-Volunteer-Trial-for-APG990-and-Provide-Combination-Strategy-Update-on-March-3-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","APGE","BK4588","BK4596","HST","BK4181","BK4585","BK4595","BK4600","BK4139","STRK","BK4516","BK4023"],"gpt_icon":1},{"id":"2510856815","title":"Buy Rating Affirmed for Apogee Therapeutics: Promising Developments in Inflammatory Disease Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2510856815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510856815?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:05","pubTimestamp":1739189159,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Alex Thompson CFA. Alex Thompson CFA has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-apogee-therapeutics-promising-developments-in-inflammatory-disease-treatments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-apogee-therapeutics-promising-developments-in-inflammatory-disease-treatments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2508114797","title":"Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 Apex Trial of Apg777 in Patients With Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114797?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA4WC0ZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2508114720","title":"Apogee Therapeutics Inc - Part a 16-Week Proof-of-Concept Data Expected Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114720?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA4WC0ZN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2508114773","title":"Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114773","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114773?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled. Part A 16-week proof-of-concept data anticipated in mid-2025. APEX is a Phase 2 randomized, placebo-controlled clinical trial evaluating APG777, a novel, subcutaneous  extended half-life monoclonal antibody  targeting IL-13 – a critical cytokine in inflammation and a primary driver of AD, in patients with moderate-to-severe AD. The trial was designed to combine the typical Phase 2a and 2b portions of a clinical trial into a single protocol. Part A exceeded expected enrollment with 123 patients randomized 2:1 to APG777 versus placebo; patients assigned to APG777 received induction regimen dosing of 720mg at weeks 0 and 2, followed by 360mg at weeks 4 and 12 and the trial has greater than 90% power for the primary endpoint. Patients benefiting from treatment will continue to APG777 maintenance dosing, which will evaluate 3- or 6-month dosing. Part B is a placebo-controlled dose opt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-announces-first-patient-120000106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2507145608","title":"Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507145608","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507145608?lang=en_us&edition=fundamental","pubTime":"2025-01-31 04:44","pubTimestamp":1738269876,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Stocks That Will Double in 2025.In this article, we are going to take a look at where Apogee Therapeutics, Inc.  stands against the other stocks.The Fed's Probable Path and its Impact on Earnings. A lot is happening in the market, especially within the growth sectors. The launch of DeepSeek has caused significant uproar across the tech market in the United States, and with key names reporting earnings this week, investors are uncertain about how the market is going to play out in 2025. On top of that, the question mark on the Fed's future actions poses yet another blow to investor sentiment. On January 30, Jim Bullard, former St. Louis Fed president, joined Market Domination on Yahoo Finance to discuss his market thesis amid the Fed's decisions to keep rates steady.Speaking of the Fed's meeting, Kaiser suggested that the updated economic data has been in line wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-apogee-therapeutics-inc-apge-204436292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QQQ","BK4139","US7Y.BOND","NVIW.SI","QLD","US30Y.BOND","MNQmain","USAW.SI","USJW.SI","US2Y.BOND","US6M.BOND","NQmain",".IXIC","US5Y.BOND","APGE","QID","TQQQ","TSYW.SI","US12M.BOND","US10Y.BOND","US3Y.BOND","PSQ","SQQQ"],"gpt_icon":1},{"id":"2507662680","title":"Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507662680","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507662680?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenhei","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017070/0/en/Apogee-Therapeutics-to-Participate-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","SMID","BK4011","BK4139"],"gpt_icon":0},{"id":"2501733712","title":"Apogee (APOG) Stock Trades Down, Here Is Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2501733712","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501733712?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:11","pubTimestamp":1736269877,"startTime":"0","endTime":"0","summary":"Shares of architectural products company Apogee  fell 17% in the morning session after the company reported underwhelming calendar fourth-quarter 2024 results. Sales were flat year on year, and this weighed on profits as operating margin fell. In addition, its full-year EPS guidance slightly missed, suggesting the weakness might be more pronounced in the coming quarters. Overall, we think this was a challenging quarter.Apogee is down 16.9% since the beginning of the year, and at $59.22 per share, it is trading 32.1% below its 52-week high of $87.22 from November 2024. Investors who bought $1,000 worth of Apogee’s shares 5 years ago would now be looking at an investment worth $1,814.Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft  to Alphabet , Coca-Cola  to Monster Beverage  could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively unde","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-apog-stock-trades-down-171117308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0345774631.USD","LU1989773731.SGD","IE00BSNM7G36.USD","IE0009356076.USD","IE00B1BXHZ80.USD","LU0957791311.USD","LU1861127337.USD","LU1043141123.HKD","LU0128525929.USD","LU1301847155.USD","LU1564329628.SGD","SG9999015945.SGD","APGE","LU2237443465.HKD","SG9999014914.USD","LU0724617625.USD","LU1712237335.SGD","IE00BDGV0183.EUR","IE0034235188.USD","BK4576","IE00BGHQF631.EUR","IE00BFXG0V08.USD","LU2023251221.USD","LU1116320737.USD","LU1691799644.USD","LU2191332357.HKD","USJW.SI","LU1267930730.SGD","IE00B3S45H60.SGD","LU1066051811.HKD","LU1935042991.SGD","SG9999015341.SGD","IE00BYQQ9H92.USD","MNST","BK4579","LU2491050071.SGD","LU1316542783.SGD","LU2552382215.SGD","IE00B42XCP33.USD","LU0494093205.USD","LU0784385170.HKD","LU2063271972.USD","LU2362541273.HKD","LU0094547139.USD","APOG","SG9999014542.SGD"],"gpt_icon":1},{"id":"2494044556","title":"This Apogee Therapeutics Insider Increased Their Holding In The Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2494044556","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494044556?lang=en_us&edition=fundamental","pubTime":"2024-12-25 19:33","pubTimestamp":1735126413,"startTime":"0","endTime":"0","summary":"Looking at Apogee Therapeutics, Inc.'s  insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.Check out our latest analysis for Apogee Therapeutics. The Last 12 Months Of Insider Transactions At Apogee Therapeutics. It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Apogee Therapeutics we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-insider-increased-holding-113333040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2490094398","title":"Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094398?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA1D7MTM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2490091044","title":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2490091044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490091044?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA1D7MTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2490094414","title":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094414","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094414?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus mon","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994371/0/en/Apogee-Therapeutics-Announces-First-Participants-Dosed-in-Phase-1-Clinical-Trial-of-APG333-its-Novel-Half-Life-Extended-TSLP-Antibody-for-the-Treatment-of-Respiratory-and-Broader-I.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","BK4581","BK4139","IE0002270589.USD","TSLP","IE00B7SZLL34.SGD","BK4227","BK4106","BK4181","BK4551","BK4585","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1861559042.SGD","PK","BK4218","APGE","IE00BHPRN162.USD","LU1861558580.USD","BK4503","BK4554","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":55,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"APGE","fiscalQuarterEnding":"2025/03","expectedEps":-1.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.95},{"market":"US","date":"2025-03-03","symbol":"APGE","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2024-11-12","symbol":"APGE","fiscalQuarterEnding":"2024/09","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7778,"buy":0.2222,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7778,"analysts":9,"updateTime":1741924800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APGE","date":"2025-06-06","current":-10.699527,"percent":0.951435,"low":-42.099968,"twenty":-26.74614,"median":-20.193343,"eighty":-12.998374,"high":-9.181289,"avg":-20.957073,"sd":7.856766,"marketCap":2197586600},"quantilePoints":[{"date":"2023-07-14","current":-14.120082,"twenty":-14.120082,"median":-14.120082,"eighty":-14.120082,"marketCap":728904256},{"date":"2023-07-21","current":-18.011929,"twenty":-18.356106,"median":-18.157543,"eighty":-18.011929,"marketCap":929808491},{"date":"2023-07-28","current":-20.899222,"twenty":-20.280785,"median":-18.735584,"eighty":-18.04723,"marketCap":1078855761},{"date":"2023-08-04","current":-20.732342,"twenty":-20.732342,"median":-20.114656,"eighty":-18.267856,"marketCap":1070241131},{"date":"2023-08-11","current":-21.547107,"twenty":-20.865853,"median":-20.262175,"eighty":-18.356106,"marketCap":1112300797},{"date":"2023-08-18","current":-23.166822,"twenty":-21.272247,"median":-20.482022,"eighty":-18.735584,"marketCap":1195913385},{"date":"2023-08-25","current":-24.246631,"twenty":-22.764347,"median":-20.836643,"eighty":-19.947026,"marketCap":1251655111},{"date":"2023-09-01","current":-16.923199,"twenty":-22.901778,"median":-20.784492,"eighty":-18.356106,"marketCap":1162468350},{"date":"2023-09-08","current":-17.424846,"twenty":-22.791833,"median":-20.482022,"eighty":-18.04017,"marketCap":1196926871},{"date":"2023-09-15","current":-15.33711,"twenty":-22.261745,"median":-20.262175,"eighty":-17.454355,"marketCap":1053518613},{"date":"2023-09-22","current":-15.742854,"twenty":-21.87694,"median":-20.07464,"eighty":-16.946806,"marketCap":1081389476},{"date":"2023-09-29","current":-15.255962,"twenty":-21.600116,"median":-18.735584,"eighty":-16.181057,"marketCap":1047944441},{"date":"2023-10-06","current":-15.816626,"twenty":-21.327219,"median":-18.248406,"eighty":-15.736952,"marketCap":1086456906},{"date":"2023-10-13","current":-14.754315,"twenty":-21.232981,"median":-18.011929,"eighty":-15.43744,"marketCap":1013485920},{"date":"2023-10-20","current":-14.732183,"twenty":-21.097514,"median":-17.509684,"eighty":-15.343012,"marketCap":1011965691},{"date":"2023-10-27","current":-11.065736,"twenty":-21.032725,"median":-17.443289,"eighty":-15.295798,"marketCap":760114440},{"date":"2023-11-03","current":-13.714136,"twenty":-20.892548,"median":-17.107628,"eighty":-15.064155,"marketCap":942035162},{"date":"2023-11-10","current":-11.751812,"twenty":-20.860011,"median":-16.901067,"eighty":-14.764643,"marketCap":807241535},{"date":"2023-11-17","current":-12.191046,"twenty":-20.815783,"median":-16.340404,"eighty":-14.242502,"marketCap":851834915},{"date":"2023-11-24","current":-12.473884,"twenty":-20.732342,"median":-15.9863,"eighty":-13.271633,"marketCap":871597891},{"date":"2023-12-01","current":-14.149156,"twenty":-20.643994,"median":-15.77974,"eighty":-12.959786,"marketCap":988655514},{"date":"2023-12-08","current":-15.76641,"twenty":-20.320051,"median":-15.713345,"eighty":-13.06857,"marketCap":1101659195},{"date":"2023-12-15","current":-16.854248,"twenty":-20.280785,"median":-15.705968,"eighty":-13.227243,"marketCap":1177670639},{"date":"2023-12-22","current":-18.52952,"twenty":-20.262175,"median":-15.76641,"eighty":-13.271633,"marketCap":1294728262},{"date":"2023-12-29","current":-21.77128,"twenty":-20.316166,"median":-15.824003,"eighty":-13.537135,"marketCap":1521242365},{"date":"2024-01-05","current":-20.48763,"twenty":-20.454114,"median":-15.9863,"eighty":-13.786432,"marketCap":1431548862},{"date":"2024-01-12","current":-23.098443,"twenty":-20.721111,"median":-16.285075,"eighty":-14.084509,"marketCap":1613976327},{"date":"2024-01-19","current":-23.34502,"twenty":-20.899222,"median":-16.57141,"eighty":-14.120082,"marketCap":1631205588},{"date":"2024-01-26","current":-26.1734,"twenty":-21.423171,"median":-16.854248,"eighty":-14.149156,"marketCap":1828835342},{"date":"2024-02-02","current":-24.650426,"twenty":-22.136094,"median":-16.901067,"eighty":-14.410237,"marketCap":1722419321},{"date":"2024-02-09","current":-26.833356,"twenty":-22.901778,"median":-17.107628,"eighty":-14.722084,"marketCap":1874948952},{"date":"2024-02-16","current":-25.919571,"twenty":-23.170966,"median":-17.443289,"eighty":-14.732183,"marketCap":1811099339},{"date":"2024-02-23","current":-25.462679,"twenty":-23.458155,"median":-17.594521,"eighty":-14.738085,"marketCap":1779174532},{"date":"2024-03-01","current":-25.252364,"twenty":-23.903055,"median":-18.011929,"eighty":-14.745463,"marketCap":1764478986},{"date":"2024-03-08","current":-39.349598,"twenty":-24.476372,"median":-18.248406,"eighty":-14.75284,"marketCap":3304775976},{"date":"2024-03-15","current":-39.31944,"twenty":-25.034796,"median":-18.52952,"eighty":-14.795627,"marketCap":3302243192},{"date":"2024-03-22","current":-40.133695,"twenty":-25.237859,"median":-19.967125,"eighty":-14.977105,"marketCap":3370628348},{"date":"2024-03-28","current":-41.080642,"twenty":-25.310382,"median":-20.039026,"eighty":-15.024319,"marketCap":3450157751},{"date":"2024-04-05","current":-35.585933,"twenty":-25.583066,"median":-20.203754,"eighty":-15.040549,"marketCap":2988684589},{"date":"2024-04-12","current":-40.39061,"twenty":-25.977589,"median":-20.297181,"eighty":-15.087984,"marketCap":3392205375},{"date":"2024-04-19","current":-33.647243,"twenty":-26.134238,"median":-20.48763,"eighty":-15.119386,"marketCap":2825863713},{"date":"2024-04-26","current":-30.802638,"twenty":-26.87687,"median":-20.704265,"eighty":-15.154157,"marketCap":2586959527},{"date":"2024-05-03","current":-35.061005,"twenty":-31.417884,"median":-20.865853,"eighty":-15.223502,"marketCap":2944598502},{"date":"2024-05-10","current":-35.544605,"twenty":-33.702281,"median":-21.144633,"eighty":-15.273667,"marketCap":2985213654},{"date":"2024-05-17","current":-30.341768,"twenty":-33.2059,"median":-21.423171,"eighty":-15.316454,"marketCap":3142011451},{"date":"2024-05-24","current":-25.989488,"twenty":-32.751748,"median":-21.791716,"eighty":-15.341537,"marketCap":2691315483},{"date":"2024-05-31","current":-26.170128,"twenty":-32.249341,"median":-22.218395,"eighty":-15.347905,"marketCap":2710021411},{"date":"2024-06-07","current":-23.773834,"twenty":-31.497141,"median":-22.764347,"eighty":-15.361417,"marketCap":2461875577},{"date":"2024-06-14","current":-24.341154,"twenty":-31.168024,"median":-22.917136,"eighty":-15.378422,"marketCap":2520623884},{"date":"2024-06-21","current":-21.479149,"twenty":-30.802638,"median":-22.901778,"eighty":-15.396128,"marketCap":2224251827},{"date":"2024-06-28","current":-22.551696,"twenty":-30.67474,"median":-22.901778,"eighty":-15.416784,"marketCap":2335318278},{"date":"2024-07-05","current":-21.168675,"twenty":-30.454668,"median":-22.551696,"eighty":-15.452028,"marketCap":2192101012},{"date":"2024-07-12","current":-25.927394,"twenty":-30.290963,"median":-22.599678,"eighty":-15.490824,"marketCap":2684885320},{"date":"2024-07-15","current":-27.107194,"twenty":-30.240158,"median":-22.64766,"eighty":-15.512581,"marketCap":2807058416},{"date":"2024-08-02","current":-25.825784,"twenty":-30.189354,"median":-22.706004,"eighty":-15.534337,"marketCap":2674363235},{"date":"2024-08-09","current":-22.78314,"twenty":-29.894686,"median":-22.901778,"eighty":-15.586554,"marketCap":2359285249},{"date":"2024-08-16","current":-22.360657,"twenty":-29.660984,"median":-22.773744,"eighty":-15.598555,"marketCap":2649402436},{"date":"2024-08-23","current":-23.604561,"twenty":-29.231009,"median":-22.862169,"eighty":-15.66023,"marketCap":2796786413},{"date":"2024-08-30","current":-24.399278,"twenty":-28.636347,"median":-22.994085,"eighty":-15.707443,"marketCap":2890948398},{"date":"2024-09-06","current":-23.811878,"twenty":-28.151516,"median":-23.098851,"eighty":-15.725149,"marketCap":2821350409},{"date":"2024-09-13","current":-24.28081,"twenty":-27.512504,"median":-23.170966,"eighty":-15.752276,"marketCap":2876911828},{"date":"2024-09-20","current":-26.136794,"twenty":-27.110581,"median":-23.268758,"eighty":-15.786496,"marketCap":3096818079},{"date":"2024-09-27","current":-28.649283,"twenty":-28.484417,"median":-23.34502,"eighty":-15.822528,"marketCap":3394510318},{"date":"2024-10-04","current":-28.061884,"twenty":-28.569318,"median":-23.434542,"eighty":-15.893348,"marketCap":3324912329},{"date":"2024-10-11","current":-26.610663,"twenty":-28.484417,"median":-23.533922,"eighty":-16.011479,"marketCap":3152964356},{"date":"2024-10-18","current":-27.755844,"twenty":-28.448831,"median":-23.612583,"eighty":-16.121447,"marketCap":3288651192},{"date":"2024-10-25","current":-25.643182,"twenty":-28.355515,"median":-23.773834,"eighty":-16.274009,"marketCap":3038332374},{"date":"2024-10-31","current":-27.099339,"twenty":-28.252419,"median":-23.811878,"eighty":-16.385155,"marketCap":3210865204},{"date":"2024-11-08","current":-28.654219,"twenty":-28.465143,"median":-23.860074,"eighty":-16.567059,"marketCap":3395095175},{"date":"2024-11-15","current":-19.789128,"twenty":-28.485404,"median":-23.853973,"eighty":-16.630879,"marketCap":2902332924},{"date":"2024-11-22","current":-16.628998,"twenty":-28.465143,"median":-23.803477,"eighty":-16.671147,"marketCap":2438858722},{"date":"2024-11-29","current":-17.517481,"twenty":-28.399895,"median":-23.76973,"eighty":-16.839744,"marketCap":2569166386},{"date":"2024-12-06","current":-18.297329,"twenty":-28.288946,"median":-23.604561,"eighty":-16.854248,"marketCap":2683541235},{"date":"2024-12-13","current":-17.195455,"twenty":-28.106309,"median":-23.497667,"eighty":-16.861788,"marketCap":2521936971},{"date":"2024-12-20","current":-18.243012,"twenty":-28.061884,"median":-23.417542,"eighty":-16.878936,"marketCap":2675574828},{"date":"2024-12-27","current":-18.305089,"twenty":-28.042139,"median":-23.34502,"eighty":-16.878936,"marketCap":2684679293},{"date":"2025-01-03","current":-18.29345,"twenty":-27.898004,"median":-23.314068,"eighty":-16.905494,"marketCap":2682972206},{"date":"2025-01-10","current":-19.092697,"twenty":-27.799282,"median":-23.175118,"eighty":-16.935003,"marketCap":2800192201},{"date":"2025-01-17","current":-14.239016,"twenty":-27.785817,"median":-23.13304,"eighty":-16.857264,"marketCap":2088336797},{"date":"2025-01-24","current":-15.60084,"twenty":-27.774326,"median":-23.084739,"eighty":-16.58873,"marketCap":2288066011},{"date":"2025-01-31","current":-16.489324,"twenty":-27.755844,"median":-22.901778,"eighty":-16.251878,"marketCap":2418373675},{"date":"2025-02-07","current":-16.155657,"twenty":-27.743997,"median":-22.822654,"eighty":-16.03771,"marketCap":2369437172},{"date":"2025-02-14","current":-14.068303,"twenty":-27.666994,"median":-22.64766,"eighty":-15.83959,"marketCap":2063299516},{"date":"2025-02-21","current":-13.17206,"twenty":-27.548527,"median":-22.532767,"eighty":-15.742854,"marketCap":1931853794},{"date":"2025-02-28","current":-11.845154,"twenty":-27.262231,"median":-22.345048,"eighty":-15.697836,"marketCap":1737245842},{"date":"2025-03-07","current":-11.30201,"twenty":-27.112839,"median":-22.212997,"eighty":-15.60472,"marketCap":2058615932},{"date":"2025-03-14","current":-12.223647,"twenty":-27.107194,"median":-21.977899,"eighty":-15.577851,"marketCap":2226488393},{"date":"2025-03-21","current":-12.874214,"twenty":-27.104275,"median":-21.832491,"eighty":-15.410728,"marketCap":2344986602},{"date":"2025-03-28","current":-12.51704,"twenty":-27.099339,"median":-21.774807,"eighty":-15.344488,"marketCap":2279928762},{"date":"2025-04-04","current":-11.158503,"twenty":-27.089467,"median":-21.479149,"eighty":-15.267174,"marketCap":2032476621},{"date":"2025-04-11","current":-9.54803,"twenty":-27.02252,"median":-21.347709,"eighty":-15.123173,"marketCap":1739135468},{"date":"2025-04-17","current":-10.217731,"twenty":-27.018004,"median":-21.19592,"eighty":-15.044975,"marketCap":1861118918},{"date":"2025-04-25","current":-11.815448,"twenty":-27.009303,"median":-21.066101,"eighty":-14.75284,"marketCap":2152136576},{"date":"2025-05-02","current":-12.501095,"twenty":-26.955194,"median":-20.851248,"eighty":-14.659715,"marketCap":2277024394},{"date":"2025-05-09","current":-12.057816,"twenty":-26.905994,"median":-20.676189,"eighty":-14.171382,"marketCap":2196282968},{"date":"2025-05-16","current":-11.538128,"twenty":-26.893009,"median":-20.509211,"eighty":-14.009329,"marketCap":2369827680},{"date":"2025-05-23","current":-11.469666,"twenty":-26.845089,"median":-20.320051,"eighty":-13.400194,"marketCap":2355766140},{"date":"2025-05-30","current":-10.709474,"twenty":-26.800437,"median":-20.280785,"eighty":-13.20517,"marketCap":2199629509},{"date":"2025-06-06","current":-10.699527,"twenty":-26.74614,"median":-20.193343,"eighty":-12.998374,"marketCap":2197586600}],"updateTime":1749437341712}}}